These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24313319)

  • 1. Pretransplant C-reactive protein as A prognostic marker in allogeneic stem cell transplantation.
    Jordan KK; Christensen IJ; Heilmann C; Sengeløv H; Müller KG
    Scand J Immunol; 2014 Mar; 79(3):206-13. PubMed ID: 24313319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation.
    Akı ŞZ; Suyanı E; Bildacı Y; Çakar MK; Baysal NA; Sucak GT
    Clin Transplant; 2012; 26(5):E513-21. PubMed ID: 23061760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT.
    Sato M; Nakasone H; Oshima K; Ishihara Y; Wada H; Sakamoto K; Kawamura K; Ashizawa M; Machishima T; Terasako K; Kimura S; Kikuchi M; Okuda S; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Kako S; Nishida J; Kanda Y
    Bone Marrow Transplant; 2013 May; 48(5):698-702. PubMed ID: 23042494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
    Shimoni A; Nagler A
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.
    Eom KS; Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Lee S
    Am J Hematol; 2013 Aug; 88(8):634-41. PubMed ID: 23620000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.
    Wang X; Liu H; Li L; Geng L; Ding K; Liu X; Tong J; Zhu W; Sun Z
    Eur J Haematol; 2012 Jan; 88(1):39-45. PubMed ID: 21933279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
    Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.
    Satwani P; Jin Z; Duffy D; Morris E; Bhatia M; Garvin JH; George D; Bradley MB; Harrison L; Petrillo K; Schwartz J; Foley S; Hawks R; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):552-61. PubMed ID: 23253557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
    McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
    Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
    Leukemia; 2006 Feb; 20(2):322-8. PubMed ID: 16307018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.
    Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
    Bone Marrow Transplant; 2003 Aug; 32(4):349-54. PubMed ID: 12900770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
    Corradini P; Zallio F; Mariotti J; Farina L; Bregni M; Valagussa P; Ciceri F; Bacigalupo A; Dodero A; Lucesole M; Patriarca F; Rambaldi A; Scimè R; Locasciulli A; Bandini G; Gianni AM; Tarella C; Olivieri A
    J Clin Oncol; 2005 Sep; 23(27):6690-8. PubMed ID: 16170177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.